Literature DB >> 9365423

Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential.

G Tunnicliff1.   

Abstract

OBJECTIVE: This review highlights the biochemistry, pharmacology, and toxicology of the naturally-occurring fatty acid derivative, gamma-hydroxybutyrate (GHB). GHB is derived from gamma-aminobutyric acid (GABA) and is proposed to function as an inhibitory chemical transmitter in the central nervous system. CONTENT: When administered in pharmacological doses, its powerful central nervous system depressant effects are readily observed. Although some of the neurophysiological actions of GHB could involve alterations in dopaminergic transmission in the basal ganglia, both its physiological and pharmacological actions are probably mediated through specific brain receptors for GHB. In addition, GHB might mediate some of its effects through interaction with the GABA(B) receptor. Experimentally, GHB has been used as a model for petit mal epilepsy; clinically, it has been used as a general anesthetic and as a drug to treat certain sleep disorders and related conditions. Owing to the purported ability of GHB to induce a state of euphoria, recreational use of this substance is popular. Although no deaths or long-term problems have been associated with GHB abuse, symptoms of GHB intoxication can be severe. The continued potential for GHB abuse makes it imperative for clinical toxicologists to be aware of the effects of this agent. Future research on the mechanism of action of GHB is needed to elucidate both its central nervous system depressant properties and its ability to effect a state of well-being.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365423     DOI: 10.3109/15563659709001236

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  10 in total

Review 1.  Complementary alternative medicine and nuclear medicine.

Authors:  Ursula Werneke; V Ralph McCready
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 2.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

3.  Gamma-hydroxybutyrate and ethanol effects and interactions in humans.

Authors:  Dung Thai; Jo Ellen Dyer; Neal L Benowitz; Christine A Haller
Journal:  J Clin Psychopharmacol       Date:  2006-10       Impact factor: 3.153

4.  Purification from rat liver of a novel constitutively expressed member of the aldo-keto reductase 7 family that is widely distributed in extrahepatic tissues.

Authors:  V P Kelly; L S Ireland; E M Ellis; J D Hayes
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

Review 5.  [Gamma-hydroxybutyrate--a neurotransmitter, medicine, and drug].

Authors:  G Trendelenburg; A Ströhle
Journal:  Nervenarzt       Date:  2005-07       Impact factor: 1.214

6.  Cloning of a rat brain succinic semialdehyde reductase involved in the synthesis of the neuromodulator gamma-hydroxybutyrate.

Authors:  C Andriamampandry; J C Siffert; M Schmitt; J M Garnier; A Staub; C Muller; S Gobaille; J Mark; M Maitre
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

Review 7.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 8.  GHB acid: A rage or reprive.

Authors:  Prakhar Kapoor; Revati Deshmukh; Ipsita Kukreja
Journal:  J Adv Pharm Technol Res       Date:  2013-10

Review 9.  Metabolic Alterations Associated with γ-Hydroxybutyric Acid and the Potential of Metabolites as Biomarkers of Its Exposure.

Authors:  Suryun Jung; Suji Kim; Yujin Seo; Sooyeun Lee
Journal:  Metabolites       Date:  2021-02-10

10.  Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities.

Authors:  Luther Elliott; Christopher Keith Haddock; Stephanie Campos; Ellen Benoit
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.